A
Aurinia Pharmaceuticals Inc. (AUPH)
NGM – Real vaqt narxi. Valyuta: USD
15.99
+0.27 (1.72%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
15.99
+0.27 (1.72%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aurinia Pharmaceuticals Inc., biopharmaceutical kompaniyasi, Qo'shma Shtatlar va Yaponiyada yuqori tibbiy ehtiyojlari bo'lgan autoimmun kasalliklar bilan yashovchi odamlarga davolash usullarini taqdim etish bilan shug'ullanadi. Kompaniya kattalar bemorlarni faol lupus nefritini davolash uchun og'iz orqali qabul qilinadigan terapiya bo'lgan LUPKYNIS (voklosporin) ni taklif etadi. Shuningdek, u autoimmun kasalliklarni potentsial davolash uchun B-hujayralar faollashtiruvchi omil va ko'payishni rag'batlantiruvchi ligandning er-xotin inhibitori bo'lgan aritinerseptni ishlab chiqmoqda. Kompaniya 1993 yilda tashkil etilgan va shtab-kvartirasi Kanadaning Edmonton shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Mr. Kevin C. Tang | Chairman & CEO |
| Mr. Michael S. Hearne CPA | Chief Financial Officer |
| Mr. Peter S. Greenleaf M.B.A. | Consultant |
| Mr. Ryan Cole | Chief Operating Officer |
| Mr. Stephen P. Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer |
| Mr. Stewart M. Kroll | Chief Development Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-11 | SC TO-T/A | ef20072576_scto-ta.htm |
| 2026-05-11 | 8-K | ef20072568_8k.htm |
| 2026-05-07 | 8-K | auph-20260507.htm |
| 2026-04-21 | DEF 14A | auph-20260421.htm |
| 2026-04-13 | SC TO-T | ny20070168x1_sctot.htm |
| 2026-04-03 | 8-K | auph-20260330.htm |
| 2026-03-23 | 8-K | auph-20260320.htm |
| 2026-02-26 | 8-K | auph-20260226.htm |
| 2026-02-26 | 10-K | auph-20251231.htm |
| 2025-11-04 | 8-K | auph-20251104.htm |
| Mr. Thomas Wei | Chief Scientific Officer |